KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Cash from Operations for 6 consecutive years, with 46073000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 60.09% year-over-year to 46073000.0, compared with a TTM value of 371808000.0 through Dec 2025, down 3.52%, and an annual FY2025 reading of 371808000.0, down 3.52% over the prior year.
  • Cash from Operations was 46073000.0 for Q4 2025 at Recursion Pharmaceuticals, up from 117360000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 77388000.0 in Q1 2022 and bottomed at 131957000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 63045000.0, with a median of 64545000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 813.38% in 2021, then surged 351.63% in 2022.
  • Year by year, Cash from Operations stood at 61158000.0 in 2021, then increased by 26.83% to 44748000.0 in 2022, then tumbled by 65.54% to 74077000.0 in 2023, then plummeted by 55.82% to 115430000.0 in 2024, then skyrocketed by 60.09% to 46073000.0 in 2025.
  • Business Quant data shows Cash from Operations for RXRX at 46073000.0 in Q4 2025, 117360000.0 in Q3 2025, and 76418000.0 in Q2 2025.